Effects of Levodopa-Carbidopa Intestinal Gel Compared with Optimized Medical Treatment on Nonmotor Symptoms in Advanced Parkinson’s Disease: INSIGHTS Study
Table 1
Baseline demographics and disease characteristics in the safety population.
Demographic and baseline characteristics
LCIG n = 43
OMT n = 44
Male, n (%)
29 (67.4)
24 (54.5)
Race, n (%)
White
34 (79.1)
35 (79.5)
Black
1 (2.3)
0
Asian
8 (18.6)
9 (20.5)
Other
0
0
Age (years), mean (SD)
66.9 (7.3)
68.6 (6.2)
Age ≥65 years, n (%)
30 (69.8)
31 (70.5)
Age ≥75 years, n (%)
7 (16.3)
7 (15.9)
UPDRS total score (parts I, II, III), mean (SD)
45.5 (18.0)
47.5 (14.9)
UPDRS IV score, mean (SD)
9.1 (3.4)
8.5 (3.2)
PD duration since diagnosis (years), mean (SD)
11.7 (4.9)
11.9 (6.0)
Time since motor fluctuation onset (years), mean (SD)
5.9 (3.6)
6.1 (4.9)
MMSE, mean (SD)
27.5 (1.74)
27.7 (1.76)
BMI: body mass index, LCIG: levodopa-carbidopa intestinal gel, MMSE: Mini-Mental State Examination, OMT: optimized medical treatment, PD: Parkinson’s disease, SD: standard deviation, and UPDRS: Unified Parkinson’s Disease Rating Scale.
